Abstract:The study by Wagner et al. (https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1416319/full) employs advanced imaging techniques to visualize clot structures in extracorporeal membrane oxygenation (ECMO) devices, revealing the importance of platelet-leukocyte aggregates and von Willebrand factor in clot stability and dissolution. This work underscores the dynamic nature of thrombus formation, where mechanical forces and cellular components interact to influence clot architecture and stability. Similarly, the research by Yuan et al. (https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1165589/full) delves into the role of Toll-like receptor 4 (TLR4) in thrombus resolution, highlighting the receptor's involvement in mediating inflammatory responses necessary for thrombus breakdown. In recent years, extensive research has explored the link between inflammation and thrombosis, revealing that the immune and coagulation systems are functionally interconnected (5). The study demonstrates that TLR4 deficiency impairs thrombus resolution in a mouse model, emphasizing the importance of inflammation and immune signaling in the clearance of thrombi. This finding aligns with the broader understanding that thrombosis is not merely a hemostatic event but also an inflammatory process, where immune cells and cytokines play pivotal roles (6)(7)(8)(9).A review by Khattak et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2024.1287553/full) further underscores the complex role of platelets in microvascular thrombosis during ST-elevation myocardial infarction (STEMI). The authors discuss how platelets, beyond their hemostatic function, contribute to inflammatory processes and microvascular obstruction, complicating recovery after myocardial infarction. Despite the widespread use of dual antiplatelet therapy, its effect on microvascular thrombosis remains unclear, driving the need for novel therapies targeting specific platelet receptors such as GPVI and PAR4. These emerging treatments show promise in mitigating microvascular damage with a lower risk of bleeding complications, offering new avenues for enhancing therapeutic strategies in STEMI management.The interplay between coagulation, inflammation and oxidative stress is further explored in the review by Bettiol et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1325002/full), which examines the regulatory role of SIRT1 in thrombosis. SIRT1, a NAD+-dependent deacetylase, modulates key processes such as endothelial activation, platelet aggregation, and inflammatory response, thereby influencing thrombus formation and stability. This review puts SIRT1 as a potential therapeutic target, suggesting that modulating its activity could offer new avenues for preventing and treating thrombotic diseases.While these studies focus on the molecular and cellular underpinnings of thrombosis, other contributions in this collection address the clinical implications of these mechanisms. Wu et al.'s multicenter retrospective cohort study (https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1373635/full) evaluates the efficacy and safety of direct oral anticoagulants (DOACs) compared to low-molecularweight heparin (LMWH) in preventing venous thromboembolism in hospitalized cancer patients. The results suggest that DOACs may offer a safer and more effective alternative to traditional therapies, highlighting the need for personalized treatment approaches based on a deeper understanding of the patient's thrombotic risk profile and the molecular characteristics of their condition.Moreover, the impact of novel therapeutic strategies on thrombosis is exemplified in the study by Rodenas et al.(https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2023.1182925/full), which investigates the use of venetoclax, a potent hepsin inhibitor, to reduce the metastatic and prothrombotic phenotypes of colorectal cancer cells. This research bridges the gap between oncology and thrombosis (10), demonstrating how targeted therapies can simultaneously address tumor progression and thrombotic risk, reflecting the interconnected nature of these pathophysiological processes.Collectively, the articles published in this Research Topic highlight the complexity of thrombosis as a multifaceted process involving hemostatic, inflammatory, and immune mechanisms. They also emphasize the potential of targeted therapies that go beyond traditional anticoagulation to modulate specific molecular pathways involved in thrombosis. As our knowledge of the molecular mechanisms underlying thrombosis advances, these studies offer a critical foundation for developing more targeted and effective therapeutic strategies, which will ultimately enhance patient outcomes and alleviate the public health burden of thr -Abstract Truncated-

By word of mouse: using animal models in venous thrombosis research

Murine Models of Vascular Endothelial Injury: Techniques and Pathophysiology

Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling

Comparison between Canine and Porcine Models of Chronic Deep Venous Thrombosis

A Quantitative Method for the Evaluation of Deep Vein Thrombosis in a Murine Model Using Three-Dimensional Ultrasound Imaging

The Basic Principles of Pathophysiology of Venous Thrombosis

Study on the Animal Model of Deep Venous Thrombosis at the Early Stage of Thrombus Organization

Advances in microRNA regulation of deep vein thrombosis through venous vascular endothelial cells (Review)

A vein wall cell atlas of murine venous thrombosis determined by single-cell RNA sequencing

[Evolution of deep vein thrombosis treatment from leeches to mechanical thrombectomy]

Biomarkers of Deep Venous Thrombosis

In Vivo Porcine Model of Acute Iliocaval Deep Vein Thrombosis

Venous thromboembolism: diagnostic advances and unaddressed challenges in management

Venous Thrombosis Assay in a Mouse Model of Cancer

Intravital Imaging of Thrombosis Models in Mice

A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism

State of the art in cerebral venous sinus thrombosis animal models

Transcriptomic Profiling of Femoral Veins in Deep Vein Thrombosis in a Porcine Model

Recent Advances on the Molecular Mechanism and Clinical Trials of Venous Thromboembolism

Non-coding RNAs regulating endothelial progenitor cells for venous thrombosis: promising therapy and innovation

Editorial: Molecular mechanisms of thrombosis